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A B S T R A C T
Purpose: To investigate factors associated with treatment non-adherence in Brazilian patients with
epilepsy.
Methods: Prospective cross-sectional study. We evaluated 385 epilepsy outpatients in a tertiary referral
center, 18 years or older, literate, without cognitive impairment or active psychiatric disorders, who
were independent in daily living activities. Data were analyzed with correlation tests and conjoint
analysis using multivariate logistic regression.
Results: Non-adherence rate, measured by the Morisky–Green Test, was 66.2%, a moderate-to-low
adherence level. Non-adherence was higher in men, in younger patients and in patients with
uncontrolled seizures. Increasing treatment complexity was also associated with decreased treatment
adherence.
Conclusion: Strategies designed to improve treatment adherence should address peculiarities associated
with younger ages and male gender. Physicians should be made aware that prescription of less complex
treatment regimens may result in better treatment adherence, and, therefore, better seizure control. The
challenge in adjusting AED treatment in this population is to minimize treatment complexity, thus
increasing chances for treatment adherence.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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Long-term antiepileptic drugs (AEDs) remain the mainstay of
epilepsy treatment. AEDs eliminate or reduce seizure frequency in
up to 67% of patients.1 Medication treatment for chronic diseases,
such as epilepsy, requires that patients incorporate complex
medication regimens into their daily routines. Managing medica-
tion schedules may pose a signiﬁcant burden in patients’ lives.2
AED choice should therefore be tailored to patients’ factors that
may limit medication use, such as tolerability, treatment adher-
ence and side effect proﬁle.
Non-adherence to medication treatment regimens is a world-
wide health problem. Non-adherence rates among patients with
epilepsy range from 30% to 50%.3 Clinicians treating patients with
epilepsy note that non-adherent patients report more difﬁculty in
attaining seizure control compared to adherent patients. Uncon-
trolled seizures lead to major morbidity and mortality, including* Corresponding author at: Rua Laplace No 44, apart 21B, Brooklin, Sa˜o Paulo
04622-000, Brazil. Tel.: +55 11 5093 7574/9999 59089.
E-mail address: c-maluf@uol.com.br (C.M.M. Ferrari).
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http://dx.doi.org/10.1016/j.seizure.2013.02.006not only physical injury, such as head trauma, fractures and burns,
but also psychosocial problems, such as depression, anxiety
disorders, decreased quality of life, and sudden unexpected death.
Even though educating patients to strictly follow medication
regimens is key to epilepsy treatment,3 intentional non-adherence
may also interfere with seizure control.4
Lack of seizure control is inﬂuenced by epilepsy etiology,
seizure type, comorbidities, and treatment non-adherence.5
Treatment adherence is affected by individual patient factors
(demographic and socioeconomic features, as well as perception
and beliefs about epilepsy), disease features (seizure frequency
and severity), medication use (number of daily doses and side
effects), and factors related to patient–provider relationship.6
Seizure control is also affected by the treatment gap, deﬁned as the
proportion of people with epilepsy who require treatment but do
not receive it. Treatment gap is inﬂuenced by access to and quality
of medical care, as well as cultural differences and stigma
associated with epilepsy.7
Non-adherence studies in patients with epilepsy have not
systematically accounted for the wide range of variables related to
patients, disease, and treatment features. Few studies have been
conducted in Brazil on treatment non-adherence in patients withvier Ltd. All rights reserved.
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ment of strategies to improve treatment adherence, with conse-
quent better seizure control.
We studied treatment non-adherence factors in patients with
epilepsy and determined its association with patients, disease,
treatment features, as well as with social support issues.
2. Methods
The study was approved by the institutional review board
(CAPPesq, Process number 210/09), and was performed in
accordance with the 1964 Declaration of Helsinki (and succeeding
revisions) ethics parameters. Written informed consent was
obtained from all patients prior to study inclusion. Anonymity
was assured.
This is a prospective, cross-sectional study using descriptive and
correlation analyses, conducted in an epilepsy outpatient clinic in a
university-afﬁliated, tertiary referral hospital in Sa˜o Paulo, Brazil.
This clinic receives referrals from other specialty clinics from the
Hospital Complex and from neurologists in the public system. Most
patients are referred if patients’ seizures are not controlled after
perceived optimal treatment with antiepileptic drugs. Since January
2002, 4882 new cases have been evaluated, and, as of July 2012, 1851
patients were followed in the clinic. Patients who attain seizure
control or are considered optimally controlled are counter-referred
to the original service. This clinic population is, therefore, heavily
biased toward very refractory epilepsy cases.
Eligibility criteria were: diagnosis of epilepsy according to the
International League Against Epilepsy (ILAE) criteria,8 age 18
years, independence in daily living activities, and absence of major
cognitive impairment or active psychiatric disorders. These
inclusion criteria were chosen to ensure that patients would be
able to understand and respond to questions from the study
instruments, which were read to the patient. Exclusion criteria
were: presence of a rapidly progressing neurological or medical
disorder, history of psychiatric syndromes that could limit
participation, coexisting non-epileptic psychogenic seizures,
patients not receiving AEDs, and a history of signiﬁcant substance
abuse within the past year.
Sampling was nonrandom. Patients were invited to participate
while waiting for the medical consult on Epilepsy Clinic days. All
patients fulﬁlling eligibility criteria, and who attended the epilepsy
clinic after study onset were included in the study, until the
estimated enrolment number of patients was reached. All patients
who met eligibility criteria and attended the epilepsy clinic
between July 2009 and February 2010 (n = 385 patients) were
included in the study.
2.1. Sample size calculation
To calculate sample size, non-adherence rate was chosen as the
primary endpoint. We calculated a conservative sample size,
assuming a 50% non-adherence rate, with a 95% conﬁdence
interval and a 5% signiﬁcance level. This yielded a sample size of
385 patients.9
Therapeutic adhesion was considered the dependent variable.
Morisky–Green Test was used to assess treatment adherence.10
This is a simple four-item questionnaire assessing non-adherence
behavior. Adherence was classiﬁed as high if all four questions
were answered as ‘‘no’’, moderate if one or two questions were
answered as ‘‘yes’’, and low if more than two questions were
answered as ‘‘yes’’. Patients with moderate or low adherence were
considered non-adherent.
Independent variables included demographic, disease-related,
family support, medication related, and health care system
variables.Demographic variables included: age (in years, on the interview
day); gender, marital status, categorized as married (in a stable
relation) or unmarried (single, widowed or separated); race, self-
referred as White (including Asians) or non-White; religion was
based on self-classiﬁcation as religious or nonreligious; education
was categorized as 4 or less years of schooling and more than 4
years of schooling; work status was categorized as employed
(included self-employed) or not employed (retired, unemployed,
on health-beneﬁt, never employed, student and homemaker); per
capita income was calculated according to patient’s information
regarding total family income divided by the number of people
living on this income.
Disease related variables included: medical diagnosis (obtained
through chart review, considering ILAE classiﬁcation),8 disease and
treatment duration in years (including periods without AED
treatment), previous 30-day seizure frequency (according to
patient’s information, categorized as at least one seizure in the
previous 30 days or no seizures during this period), patient
perception of seizure control (categorized as controlled or
uncontrolled/not always controlled), seizure control (classiﬁed
as controlled: no seizures in the previous 6 months or uncon-
trolled: at least one seizure in the previous 6 months).
Family support was categorized as continuous/almost continu-
ous friends and family support or rare/absent support.
Medication related included number of AEDs (categorized as
mono- or polytherapy), therapeutic complexity (measured by
the EMTCI scores, according to the original instrument’s scoring
guide).11
The EMTCI is a speciﬁcally designed tool to assess medication
regimen complexity in adult patients with epilepsy. EMTCI is a
four-item questionnaire, which collects information on medication
use, medication administration frequency, and special directions
and actions to ensure that medications are taken as prescribed. The
Brazilian-Portuguese version of the EMTCI, adapted for use in
Brazil, has shown good reliability and validity.12
Healthcare related variables included access to medication
(public system or private), action taken when medication is not
accessible (categorized as does not take medication or buys
medication/obtains from alternative source), frequency of
medical visits (expressed in days), difﬁculty to obtain physi-
cian’s appointment (categorized by the patient as easy or
difﬁcult), unscheduled clinic visit (categorized as always
available/never needed or rarely/never available), quality of
medical care (categorized as very good/good or bad/no opinion)
and perception of health status since initiating treatment in the
clinic (much better/better or slightly better/no improvement/
does not know).
2.2. Statistical analysis
Statistical analysis was carried out with the Statistical Package
for the Social Sciences (SPSS) 18.0 (SPSS Inc., Chicago, IL, USA).
Association between treatment adherence and nominal indepen-
dent variables was tested with Pearson’s chi-square test or
likelihood ratio statistics. Data were tested for normal distribution
with the Kolmogorov–Smirnov test and for homogeneity of
variances. Comparisons of means between high and moderate-
to-low adherence groups were performed with Student’s t-test
when variables were normally distributed; otherwise, non-
parametric Mann–Whitney test was applied.
Backward stepwise multiple logistic regression analysis was
used to identify factors associated with treatment non-adherence.
Variables associated with non-adherence (p < 0.20) were included
in the model. Model adequacy was measured with receiver-
operating characteristics (ROC) under the curve area. Statistical
tests were performed with a 5% signiﬁcance level (p < 0.05).
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3.1. Demographics
We studied 385 patients, with ages ranging from 18 to 76 years
(mean 39.7  12.6 yrs), 53.5% women, 31.9% single, 22.6% widowed
or divorced, 15.1% had at least some college education, 60.8% were
self-classiﬁed as White, 92.7% declared a religious afﬁliation; 37.9%
were employed (6.5% self-employed), monthly mean per capita
income was R$627.25 (circa US$325.00).
3.2. Epilepsy features
Regarding epilepsy syndrome classiﬁcation, 79.5% had focal
symptomatic epilepsy, (54.5% had temporal lobe epilepsy and
34.5% mesial temporal sclerosis), 8.8% had focal cryptogenic
epilepsy, 9.9% had generalized idiopathic epilepsy, and 1.8% had
generalized cryptogenic epilepsy.
Mean disease duration was 22.4 years; mean treatment
duration was 21.5 years. 40.3% of patients had been seizure-free
in the previous 30 days; 79.0% had presented seizures in the 6
months preceding the interview. However, only 41.0% of the
patients considered seizures to be not always or not at all
controlled.
3.3. AED treatment
Regarding AED numbers, 71.1% of the patients were on a two to
ﬁve AED polytherapy regimen (29.4% of patients were on a single
AED, 36.1% on two AEDs and 28.3% on three AEDs); 55.8% of
patients were on carbamazepine, 38.7% on clobazam and 35.3% on
lamotrigine. Sixty-six percent of the patients did not adhere to
treatment (Morisky–Green Test), 60.5% had moderate and 5.7% had
low adherence levels. Patients attributed non-adherence to:
forgetting doses (47.5%), lack of time to take AEDs (39.2%),
worsening symptoms (9.0%), and symptom improvement (8.5%).
Comparison of independent variables between high and moderate-
to-low adherence groups is displayed in Table 1.
3.4. Health care variables and social support issues
The majority of patients (60.8%) declared it was easy to
schedule a clinic visit after the initial appointment, and that it was
always possible to schedule an emergency appointment (89.8%).
Mean interval between physician visits was 141.7  81.6 days
(range 15–360 days); 49.4% had clinic visits at 120–180 day (4–6-
month) intervals. Most patients (93.3%) considered the medical
consult as good or very good. 83.1% attributed improvement or great
improvement in their health condition after starting treatment in the
clinic.
96.1% of participants received free medication from the public
service; 82.1% buy medication if free medication is not available.
Treatment complexity mean, measured by EMTCI was 14.7  8.0
points (range 2.0–44.0).
The majority of patients declared that they always (63.6%) or
nearly always (9.4%) had family or friends support. We found no
statistically signiﬁcant association between family members or
friends support and treatment adherence.
We found no statistically signiﬁcant association between
demographic features (gender, marital status, race, religion,
education level and occupational status) and treatment adherence
level on univariate analysis (Table 1).
Adherence was signiﬁcantly associated with seizure occurrence
in the previous 30 days, seizure control, and treatment regimen
(Table 1). Compared with patients in the high adherence group,
patients in the moderate-to-low adherence group reported ahigher seizure frequency in the previous 30 days (64.7% vs. 50.0%),
uncontrolled seizures (83.9% vs. 69.2%), and being on AED
polytherapy (76.1% vs. 61.5%). Mean patients’ age in the moder-
ate-to-low adherence group was signiﬁcantly lower (p < 0.001)
than that of patients in the high adherence group. Treatment
regimen complexity, assessed by the EMTCI, was signiﬁcantly
higher (p < 0.001) in the moderate-to-low adherence group.
Multiple regression analysis model included all factors with
p < 0.20, namely: gender, race, seizure occurrence in the previous
30 days, controlled seizures, perception of seizure control,
medication regimen, number of physicians visits, and treatment
regimen complexity index (EMTCI). Multiple logistic regression
analysis results are summarized in Table 2. Four variables were
signiﬁcantly associated with treatment adherence: gender, age,
seizure control status, and treatment regimen complexity. Non-
adherence was less frequent among older patients; a 1-year
increment in age was associated with a 3% decrease in treatment
non-adherence probability. Non-adherence was also more com-
mon among individuals who had to follow more complex
treatment regimens; a one-point increment in EMTCI score was
associated with a 6% increase in treatment non-adherence
probability.
Area under ROC curve was 0.69 (95% CI = 0.64–0.75; p = 0.000).
Correct prediction of adherence and non-adherence model was
68.3%. Percentage of correct classiﬁcation was 91.8% for non-
adherence and 22.3% for adherence to treatment.
4. Discussion
In this study, 66.2% of patients with epilepsy had moderate to
low level of adherence to treatment, as assessed by the Morisky–
Green Test. Other studies that used the same test have reported
59%,13 58%14 treatment adherence in people with epilepsy.
Another study,15 using a different instrument to measure
adherence, found a 68.5% non-adherence rate in outpatients with
juvenile myoclonic epilepsy.
Measuring adherence is a complex task.16 In the absence of a
gold standard, multiple tools are utilized to assess adherence. Pill
or reﬁll count may overestimate adherence, since patients may
discard pills, instead of taking medication.17 Computerized
pharmacy databases are more informative of medication acquisi-
tion rather than intake.18 Medication diaries are of limited use to
evaluate adherence, since the majority of patients do not follow
instructions or ﬁll diaries immediately before physician appoint-
ments.19 Patients’ or caregiver’s reports are subjective and may
overestimate adherence.18 Measuring AED plasma levels is
invasive, and impractical for large populations.20,21,29 Decreased
medication levels in the postictal period have been associated with
low adherence and breakthrough seizures. Medication intake
under direct supervision can only be accomplished on once-daily
regimens, in hospitalized patients or for patients under continuous
nursing care. Adherence questionnaires are practical, inexpensive,
easily applicable, and, therefore, commonly used in clinical
practice and research.16,22
The Morisky–Green Test has been widely used to assess
treatment adherence in patients with other chronic diseases, thus
allowing comparison of adherence between different patient
populations. The Morisky–Green Scale relies solely on patient’s
report of perceived adherence. Patient’s perception of adherence
may be erroneous, especially in patients with memory impairment,
such as people with epilepsy.23 The Morisky–Green Scale has been
referred to as blunt and naı¨ve.24 Additionally, it was originally
validated in a population skewed toward Blacks (91%), women
(70%), and patients with relatively little education (8 years mean).10
Medication intake is not veriﬁed. However, it is internally valid, and
is a quick and easy method to assess adherence. Non-adherence
Table 1
Comparison of variables between high and moderate-to-low adherence groups.
Variables Treatment adherence p-Value
High Moderate-to-low
Age (years), mean (SD) 42.4 (13.0) 38.2 (12.1) 0.001c
Gender
Man 51 (28.5%) 128 (71.5%) 0.053a
Woman 79 (38.3%) 127 (61.7%)
Marital status
Married 61 (34.8%) 114 (65.2%) 0.760a
Unmarried 69 (32.8%) 141 (67.2%)
Race
White/Asian 87 (36.6%) 151 (63.4%) 0.173a
Black/Mulatto 43 (29.3%) 104 (70.7%)
Religion
Religious 124 (34.7%) 233 (65.3%) 0.220a
Non-religious 6 (21.4%) 22 (78.6%)
Education level
Less than 4 years 53 (37.1%) 90 (62.9%) 0.347a
More than 4 years 77 (31.8%) 165 (68.2%)
Occupational status
Employed 47 (32.2%) 99 (67.8%) 0.690a
Unemployed 83 (34.7%) 156 (65.3%)
Monthly income (R$), mean (SD) 618.8 (905.2) 631.0 (828.5) 0.976c
Epilepsy syndrome
Symptomatic focal epilepsy 96 (31.4%) 210 (68.6%) 0.205b
Cryptogenic focal epilepsy 16 (47.1%) 18 (52.9%)
Idiopathic generalized epilepsy 16 (42.1%) 22 (57.9%)
Cryptogenic generalized 2 (28.6%) 5 (71.4%)
Time since diagnosis (years), mean (SD) 23.4 (14.7) 22.0 (12.8) 0.205d
Treatment duration (years), mean (SD) 22.0 (13.9) 21.2 (12.8) 0.710c
Seizures in the previous 30 days
No seizures 65 (41.9%) 90 (58.1%) 0.008a
With seizures 65 (28.3%) 165 (71.7%)
Seizure control
Controlled 40 (49.4%) 41 (50.6%)
Uncontrolled 90 (29.6%) 214 (70.4%) 0.001a
Perception of seizure control
Controlled 83 (36.6%) 144 (63.4%)
Uncontrolled (uncontrolled/not always controlled) 47 (29.7%) 111 (70.3%) 0.200a
Treatment regimen
Monotherapy 50 (45.1%) 61 (54.9%) 0.004a
Polytherapy 80 (29.2%) 194 (70.8%)
EMTCI, mean (SD) 12.3 (6.4) 16.1 (8.5) <0.000d
Family members or friends support
Yes (continuous/almost continuous) 93 (33.1%) 188 (66.9%) 0.737a
No (rare/absent support) 37 (35.6%) 67 (64.4%)
Easiness scheduling clinic appointments
Yes 79 (33.8%) 155 (66.2%) 1.000a
Sometimes/no 51 (33.8%) 100 (66.2%)
Interval between physician visits (days), mean (SD) unscheduled clinic visit 153.3 (91.5) 135.8 (74.7) 0.135c
Yes (always available/rarely/never needed) 116 (33.5%) 230 (66.5%) 0.906a
No (never available) 14 (35.9%) 25 (64.1%)
Medical care
Very good/good 122 (34.0%) 237 (66.0%) 0.905 a
Bad/no opinion 8 (30.8%) 18 (69.2%)
Perception of health status after beginning treatment in outpatient clinic
Improvement (much better/better) 208 (81.6%) 47 (18.4%)
No improvement (slightly better/no improvement/does not know) 112 (86.2%) 18 (13.8%) 0.321a
Medication source (cost-free)
Public health services 124 (33.5%) 246 (66.6%) 0.809a
Private health services 6 (40.0%) 9 (60.0%)
Patient’s action when free AEDs are unavailable
Purchase 109 (34.5%) 207 (65.5%) 0.613a
Does not take medication 21 (30.4%) 48 (69.6%)
SD: standard deviation; EMTCI: Epilepsy Medication and Treatment Complexity Index.
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from 28% to 85.8%.25–29 The lowest reported non-adherence rate
(28%) was noted in a study with 61 adult patients treated with oral
antineoplastic agents.25Adherence studies have also incorporated the use of prescrip-
tion records to identify patients who were ordering medication
less frequently than expected.30 In our institution, patients receive
free medication on a monthly basis, either by collecting the drugs
Table 2
Logistic regression model for estimation of association of age, seizures’ control and




Gender (women) 0.48 0.037 0.62 0.39–0.97
Seizure control (controlled) 0.56 0.041 0.57 0.33–0.98
EMTCI 0.61 0.000 1.06 1.03–1.10
Age 0.27 0.003 0.97 0.96–0.99
B: variable coefﬁcient; OR: odds ratio; CI: conﬁdence interval; EMTCI: Epilepsy
Medication and Treatment Complexity Index.
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system. If patients miss a clinic appointment, they will not be able
to obtain medication unless they present to an unscheduled clinic
appointment. Since the total number of pills is dispensed monthly,
we were unable to use this measure to verify treatment adherence.
We did not ﬁnd a signiﬁcant association between frequency of
clinic appointments and adherence. We did not control for
absenteeism; our study population included only patients who
showed up for the clinic appointment. Since in our clinic all
patients are allowed unscheduled appointments if they present
unexpected changes in clinical condition or may run out of
medication. In this scenario, frequency of clinic appointments
would be more related to clinical condition, and less likely to be
associated with treatment adherence.31
We also did not ﬁnd an association between friends and family
support and adherence. We observed high levels of perceived
friends and family support (around 72%) for both groups of
adherent and non-adherent patients. Patients with controlled
seizures reported less family and friends support than patients
with uncontrolled seizures, underscoring the role of family and
friends support in this patient group.
Employment status did not differ among low and high
adherence patients groups. In fact, employment rate in this study
was surprisingly high, considering the proﬁle of a population of
patients with very refractory epilepsy. We did not include patients
with intellectual disabilities. Our patient population is therefore
biased towards patients who might be more likely to work.
Another caveat is that our methods considered self-employed
patients were considered as employed. One may speculate that,
since disability and disease beneﬁts may be hard to obtain in Brazil,
and may also provide insufﬁcient funds to allow subsistence,
patients with refractory epilepsy may need to obtain additional
income in the informal market, sometimes helping a family
member. These patients will consider themselves employed and
generating income. These issues should be investigated with
appropriate methodology.
In the present study, the most common reasons for non-
adherence to treatment regimens were forgetting to take the
medication. Non-adherence was attributed to forgetting to take
medication for 47.5% of patients, and lack of time to take
medications for 39.2% of patients. A postal survey study with
661 adults assessed non-adherence and consequences of inade-
quate AED treatment compliance in epilepsy patients.32 This
survey consisted of 10 direct questions on medication dosing and
possibility of seizure occurrence after omitted doses. 66% of
patients reported taking more than four pills per day, 71% reported
missing a dose of medication at least once, 32% informed doctors
when they missed doses, and 45% reported seizure occurrence as a
consequence of missing an AED dose.
Cognitive and memory problems have also been found to be a
signiﬁcant reason for non-adherence than unwillingness or
carelessness to take medication.33 In that study, the overwhelming
majority of patients was willing to regularly take medication.Self-reported AED adherence was assessed with an online
survey in which 408 epilepsy patients were asked whether or not
they missed or stopped a AED dose in the previous week, month,
and 3 months,6 29% of patients were classiﬁed as non-adherent,
and 72% reported forgetting doses as the main AED non-adherence
reason.6 Brazilian studies assessing treatment adherence with the
Morisky–Green Test have also reported forgetting doses and lack of
time as the main non-adherence reason among patients with
chronic diseases other than epilepsy.27,34
Through logistic regression analysis, we found a statistically
signiﬁcant association between treatment non-adherence age,
gender, seizure control status and treatment regimen complexity,
as measured by the EMTCI. Women are more adherent to
treatment and are more accepting of the diagnosis, while men
tend to prioritize work and delay seeking medical care to avoid
unemployment.35–37
In our study, non-adherence was more common among younger
patients. One-year increments were associated with a 3% decrease in
treatment non-adherence probability. A literature review of human
immunodeﬁciency virus (HIV)-positive patients showed that
treatment adherence increased in ages up to 75 years. 38
Treatment complexity (EMTCI) was also signiﬁcantly associated
with treatment non-adherence. A one-point increase in the EMTCI
was associated with a 6% increase in treatment non-adherence
probability. The impact of the complexity of treatment regimens
on patient adherence is well documented.1,32,39–42 Treatment
complexity affects not only newly diagnosed patients, but also
those receiving long-term treatments. A study with 661 epilepsy
patients treated for a 10-year period showed a relationship
between forgetting to take medications and seizure occurrence.
This study also showed that increasing treatment complexity,
increased the likelihood of the patient forgetting to take
medications, and consequent increase in seizure occurrence
probability.37 In epilepsy and other chronic diseases, such as high
blood pressure and acquired immune deﬁciency syndrome (AIDS),
increasing treatment regimen complexity is associated with
decreased treatment adherence. As treatment complexity
increases, patients’ understanding of the regimen decreases,
leading to failure to take medications as prescribed.43–46 Treat-
ment complexity may also interfere with symptom control.
In this study, seizure frequency in the previous 30 days, as well as
seizure control status were associated with treatment non-
adherence, but only seizure control was retained in the ﬁnal
regression model. Treatment non-adherence probability was lower
among patients with seizure control. A study that compared two
epilepsy patient groups (non-adherent patients, n = 298; adherent
patients, n = 110) also found non-adherence to be associated with
reduced seizure control.6 In that study, patients who reported loss of
seizure control loss, had undergone changes in medication dose
(70%), had been switched to a new medication (61%), or had another
medication added to the treatment regimen (56%).6 Low treatment
adherence is strongly associated with uncontrolled seizures among
epilepsy patients, and with symptom recrudescence in other chronic
diseases.13 It has been shown that seizure occurrence after AED dose
omission will result in improved treatment adherence.47Although it
is widely accepted that non-adherence leads to poor seizure control,
our ﬁndings also suggest that uncontrolled seizures may, paradoxi-
cally, contribute to non-adherence.
Treatment non-adherence in people with epilepsy increases the
risk of uncontrolled seizures, injuries, emergency room visits,
hospital admissions, occurrence of status epilepticus and SUDEP,
underscoring the need for implementation of strategies to improve
adherence. Intensive reminders and implementation of intention
interventions appear promising to enhance adherence in people
with epilepsy receiving AEDs.48 Moreover, strategies designed to
improve adherence should not be limited to patient related factors,
C.M.M. Ferrari et al. / Seizure 22 (2013) 384–389 389but should also encompass provider and health care system related
factors.24
Our study adds to the scant literature of treatment adherence in
outpatient epilepsy patients in Brazil. The Morisky–Green Test,
albeit generic and biased to patient’s adherence perception, allows
comparison of adherence levels in different patient populations.24
Our results show that treatment non-adherence rates for epilepsy
patients in Brazil were similar to those for patients in other countries.
It should be kept in mind, however, that our patient population was
heavily biased toheavilymedicated patients withdifﬁcult-to-control
seizures. Caution should be exercised in extrapolating results to
different samples of people with epilepsy.
Multiple logistic regression analysis of patients, disease, treat-
ment regimen, and social support features showed that variables that
best explained treatment non-adherence were age, gender, treat-
ment complexity and seizure control status. Strategies designed to
improve treatment adherence should address peculiarities associat-
ed with younger ages and male gender. Physicians should be made
aware that prescription of less complex treatment regimens may
result in better treatment adherence, and therefore better seizure
control. Patients with medically refractory epilepsy need increasing
medication doses and AED polytherapy. The challenge in adjusting
AED treatment in this population is to minimize treatment
complexity, to increase chances for treatment adherence.
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